journal
Journal For International Medical Graduates
Journal For International Medical Graduates
California Institute of Behavioral Neurosciences and Psychology
US
https://www.cibnp.com
2832-9864
138
Articles
Comparing Safety and Efficacy of Rituximab and Eculizumab in Treating Refractory Myasthenia Gravis: A Systematic Review
Vineet Suryadevara
Suryadevara
Vineet
vineet.suryadevara@jimgs.com
Yaman Habab
Habab
Yaman
yaman.habab@jimgs.com
Alana Hutcheson
Hutcheson
Alana
alana.hutcheson@jimgs.com
Binay Panjiyar
Panjiyar
Binay
binay.panjiyar@jimgs.com
Gershon Davydov
Davydov
Gershon
gershon.davydov@jimgs.com
Hiba Nashat
Nashat
Hiba
hiba.nashat@jimgs.com
Sally Ghali
Ghali
Sally
sally.ghali@jimgs.com
Shadin Afifi
Afifi
Shadin
shadin.afifi@jimgs.com
Safeera Khan
Khan
Safeera
safeerakhan79@gmail.com
California Institute of Behavioral Neurosciences and Psychology (United States)
https://ror.org/01ytd2n62
26
09
2023
Received: 2692023
Copyright (c) 2023 Journal For International Medical Graduates
2023
Journal For International Medical Graduates
Myasthenia Gravis
Refractory Myasthenia Gravis
Rituximab
Eculizumab
Neuromuscular disease
Monoclonal antibodies
[
Young C, McGill SC. Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Apr. PMID: 34255447. https://www.ncbi.nlm.nih.gov/books/NBK571915/
]
[
Vissing J, Jacob S, Fujita KP, O'Brien F, Howard JF; REGAIN study group. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab. J Neurol. 2020 Jul;267(7):1991-2001. doi: 10.1007/s00415-020-09770-y. Epub 2020 Mar 18. PMID: 32189108; PMCID: PMC7320935.
]
[
Bastakoti S, Kunwar S, Poudel S, Quinonez J, Bista S, Singh N, Jha V, Ruxmohan S, Paesani S, Cueva W, Michel J. Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis. Cureus. 2021 Nov 9;13(11):e19416. doi: 10.7759/cureus.19416. PMID: 34909332; PMCID: PMC8660595.
]
[
Dhillon, S. Eculizumab: A Review in Generalized Myasthenia Gravis. Drugs 78, 367–376 (2018). https://doi.org/10.1007/s40265-018-0875-9
]
[
Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019 Mar 1;12:1756286419832242. doi: 10.1177/1756286419832242. PMID: 30854027; PMCID: PMC6399761.
]
[
Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018 Jan 18;11:1756285617749134. doi: 10.1177/1756285617749134. Erratum in: Ther Adv Neurol Disord. 2018 Mar 21;11:1756286418765591. PMID: 29403543; PMCID: PMC5791553.
]
[
Andersen, H., Mantegazza, R., Wang, J.J. et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual Life Res 28, 2247–2254 (2019). https://doi.org/10.1007/s11136-019-02148-2
]
[
Brauner S, Eriksson-Dufva A, Hietala MA, Frisell T, Press R, Piehl F. Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis. JAMA Neurol. 2020 Aug 1;77(8):974-981. doi: 10.1001/jamaneurol.2020.0851. PMID: 32364568; PMCID: PMC7199182.
]
[
Nelke C, Schroeter CB, Stascheit F, et al, Eculizumab versus rituximab in generalised myasthenia gravis. Journal of Neurology, Neurosurgery & Psychiatry 2022;93:548-554. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9016243/
]
[
Clinical Review Report: Eculizumab (Soliris): Alexion Pharma Canada Corporation: Indication: Adult patients with generalized myasthenia gravis [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Dec. Appendix 5, Description and Appraisal of Outcome Measures. Available from: https://www.ncbi.nlm.nih.gov/books/NBK567509/
]
[
Muppidi S, Silvestri NJ, Tan R, Riggs K, Leighton T, Phillips GA. Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve. 2022 Jun;65(6):630-639. doi: 10.1002/mus.27476. Epub 2022 Jan 6. PMID: 34989427; PMCID: PMC9302997.
]
[
Zhao C, Pu M, Chen D, Shi J, Li Z, Guo J, Zhang G. Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Front Neurol. 2021 Oct 13;12:736190. doi: 10.3389/fneur.2021.736190. PMID: 34721267; PMCID: PMC8548630.
]
[
Xiao H, Wu K, Liang X, Li R, Lai KP. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis. Front Immunol. 2021 Aug 11;12:715036. doi: 10.3389/fimmu.2021.715036. PMID: 34456922; PMCID: PMC8384962.
]
[
Randall KL. Rituximab in autoimmune diseases. Aust Prescr. 2016 Aug;39(4):131-134. doi: 10.18773/austprescr.2016.053. Epub 2016 Aug 1. PMID: 27756976; PMCID: PMC4993704.
]
[
Kusner LL, Kaminski HJ, Soltys J. Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert Rev Clin Immunol. 2008 Jan;4(1):43-52. doi: 10.1586/1744666X.4.1.43. PMID: 20477586; PMCID: PMC4375541.
]
[
Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr; REGAIN study group. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Ann Clin Transl Neurol. 2020 Aug;7(8):1327-1339. doi: 10.1002/acn3.51121. Epub 2020 Jul 22. PMID: 32700461; PMCID: PMC7448154.
]
[
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8. PMID: 30767274; PMCID: PMC6619057.
]
[
Howard JF Jr, Karam C, Yountz M, O'Brien FL, Mozaffar T; REGAIN Study Group. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Ann Clin Transl Neurol. 2021 Jul;8(7):1398-1407. doi: 10.1002/acn3.51376. Epub 2021 May 27. PMID: 34043280; PMCID: PMC8283175.
]
[
Zhao C, Pu M, Chen D, Shi J, Li Z, Guo J, Zhang G. Effectiveness and Safety of Rituximab for Refractory Myasthenia Gravis: A Systematic Review and Single-Arm Meta-Analysis. Front Neurol. 2021 Oct 13;12:736190. doi: 10.3389/fneur.2021.736190. PMID: 34721267; PMCID: PMC8548630.
]
[
Feng X, Song Z, Wu M, Liu Y, Luo S, Zhao C, Zhang W. Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis. Front Neurol. 2021 Dec 1;12:725700. doi: 10.3389/fneur.2021.725700. PMID: 34925206; PMCID: PMC8672452.
]
[
Cortés-Vicente E, Álvarez-Velasco R, Pla-Junca F, Rojas-Garcia R, Paradas C, Sevilla T, Casasnovas C, Gómez-Caravaca MT, Pardo J, Ramos-Fransi A, Pelayo-Negro AL, Gutiérrez-Gutiérrez G, Turon-Sans J, López de Munain A, Guerrero-Sola A, Jericó I, Martín MA, Mendoza MD, Morís G, Vélez-Gómez B, Garcia-Sobrino T, Pascual-Goñi E, Reyes-Leiva D, Illa I, Gallardo E. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome. Ann Clin Transl Neurol. 2022 Feb;9(2):122-131. doi: 10.1002/acn3.51492. Epub 2022 Jan 26. PMID: 35080153; PMCID: PMC8862423.
]